ramipril

Summary

Summary: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.

Top Publications

  1. Bicket D. Using ACE inhibitors appropriately. Am Fam Physician. 2002;66:461-8 pubmed
    ..ACE inhibitors are generally well tolerated and have few contraindications. (Am Fam Physician 2002;66:473.) ..
  2. Ghiadoni L, Versari D, Magagna A, Kardasz I, Plantinga Y, Giannarelli C, et al. Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens. 2007;25:361-6 pubmed
    ..was designed to evaluate the effect of 3-month treatment with a lower versus a higher antihypertensive dosage of ramipril (5 or 10 mg/day) on nitric oxide (NO)-dependent vasodilation in 46 untreated patients with essential hypertension...
  3. Schmieder R, Delles C, Mimran A, Fauvel J, Ruilope L. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351-6 pubmed
    ..rate >80 ml/min, and normo- or microalbuminuria were treated once daily with 40/80 mg telmisartan or 5/10 mg ramipril for 9 weeks...
  4. Caglar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur Rev Med Pharmacol Sci. 2011;15:1359-68 pubmed
    To compare the effects of nebivolol and ramipril on left ventricular hypertrophy in hypertensive patients...
  5. Hermida R, Ayala D. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension. 2009;54:40-6 pubmed publisher
    ..This study investigated the administration time-dependent effects of ramipril on ambulatory blood pressure. We studied 115 untreated hypertensive patients, 46.7+/-11...
  6. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte M, Perlini S. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol. 2009;53:24-9 pubmed publisher
    ..After cardioversion to sinus rhythm by intravenous propafenone, patients were randomized to either ramipril 5 mg/day (n = 31) or placebo (n = 31). Holter monitoring and clinical examination were performed every 3 months...
  7. Linz W, Schafer S, Afkham F, Gerl M, Schmidts H, Rütten H. Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst. 2006;7:155-61 pubmed
    ..rats aged 15 months were treated chronically with either the pure angiotensin-converting enzyme (ACE) inhibitor, ramipril (1 mg/kg/d in drinking water, n=46), or the vasopeptidase inhibitor AVE7688 (30 mg/kg/d in chow, n=46), or ..
  8. Faure S, Oudart N, Javellaud J, Fournier A, Warnock D, Achard J. Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil. J Hypertens. 2006;24:2255-61 pubmed
    ..5000 IU/kg, 2 and 48 h after stroke), olmesartan (10 mg/kg per day in drinking water started 36 h after stroke), ramipril (2...
  9. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res. 2011;34:145-51 pubmed publisher
    ..They were randomized to take losartan 50 mg per day or ramipril 5 mg per day for 1 month and titrated up to 100 mg per day and 10 mg per day for 13 months, respectively...

More Information

Publications60

  1. Radaelli A, Loardi C, Cazzaniga M, Balestri G, DeCarlini C, Cerrito M, et al. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination. Arterioscler Thromb Vasc Biol. 2007;27:2750-5 pubmed
    ..Patients scheduled for CABG (n=22) were randomized to statin/ACEI combination treatment at standard doses (STD, ramipril 2...
  2. Bosch J, Yusuf S, Gerstein H, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-62 pubmed
    ..disease but with impaired fasting glucose levels (after an 8-hour fast) or impaired glucose tolerance to receive ramipril (up to 15 mg per day) or placebo (and rosiglitazone or placebo) and followed them for a median of 3 years...
  3. Lawson G, Cocks E, Tanna S. Bisoprolol, ramipril and simvastatin determination in dried blood spot samples using LC-HRMS for assessing medication adherence. J Pharm Biomed Anal. 2013;81-82:99-107 pubmed publisher
    ..resolution mass spectrometry (LC-HRMS) method was developed and validated for the determination of bisoprolol, ramipril and simvastatin...
  4. Dupuis F, Vincent J, Limiñana P, Chillon J, Capdeville Atkinson C, Atkinson J. Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. J Hypertens. 2010;28:1566-73 pubmed
    ..We hypothesized that a combination of suboptimal doses of the ARB, telmisartan (TEL) and of the ACEI, ramipril (RAM), could be a well tolerated and effective treatment of hypertension-induced remodeling of cerebral arterioles...
  5. Velkoska E, Dean R, Burchill L, Levidiotis V, Burrell L. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci (Lond). 2010;118:269-79 pubmed publisher
    ..STNx and Control rats received vehicle or ramipril (1 mg. kg (-1) of body weight ...
  6. Ismael M, Talbot S, Carbonneau C, Beausejour C, Couture R. Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance. Eur J Pharmacol. 2008;589:66-72 pubmed publisher
    ..This study aimed at comparing the beneficial effects of N-acetyl-L-cysteine (NAC, antioxidant) and ramipril (angiotensin-1 converting enzyme inhibitor) on tactile and cold allodynia induced by chronic glucose feeding...
  7. Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59 pubmed publisher
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk ..
  8. Lonn E, Gerstein H, Sheridan P, Smith S, Diaz R, Mohan V, et al. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol. 2009;53:2028-35 pubmed publisher
    The aim of this study was to evaluate effects of the angiotensin-converting enzyme (ACE) inhibitor ramipril and the thiazolidinedione (TZD) rosiglitazone on carotid intima-media thickness (CIMT) in people with impaired glucose tolerance (..
  9. Martinuzzi A, Liava A, Trevisi E, Frare M, Tonon C, Malucelli E, et al. Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. Muscle Nerve. 2008;37:350-7 pubmed
    ..In a double-blind, randomized, placebo-controlled trial, we assessed the efficacy of an ACE inhibitor (2.5 mg ramipril) in 8 patients with McArdle's disease...
  10. Jenrow K, Brown S, Liu J, Kolozsvary A, Lapanowski K, Kim J. Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus. Radiat Oncol. 2010;5:6 pubmed publisher
    ..Here we investigate the angiotensin converting enzyme (ACE) inhibitor, ramipril, as a mitigator of radiation injury in this context.
  11. Mann J, Schmieder R, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53 pubmed publisher
    ..We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with ..
  12. Hathial M. Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study. Indian Heart J. 2008;60:200-4 pubmed
    To assess the safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular (CV) events by observing the levels of blood pressure (BP) and by recording the incidence of cough in these patients...
  13. Andersen K, Weinberger M, Constance C, Ali M, Jin J, Prescott M, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10:157-67 pubmed publisher
    ..of treatment based on the direct renin inhibitor, aliskiren, or the angiotensin-converting enzyme inhibitor, ramipril, on plasma renin activity (PRA), plasma renin concentration (PRC) and other biomarkers in a 26-week randomised, ..
  14. Macha S, Sennewald R, Rose P, Schoene K, Pinnetti S, Woerle H, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013;35:226-35 pubmed publisher
    ..Empagliflozin is a sodium glucose cotransporter 2 inhibitor in clinical development as a treatment for type 2 diabetes mellitus...
  15. Lee T, Greene Schloesser D, Payne V, Diz D, Hsu F, Kooshki M, et al. Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment. Radiat Res. 2012;178:46-56 pubmed
    We hypothesized that chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, to young adult male rats would prevent/ameliorate fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive ..
  16. Mutolo D, Bongianni F, Evangelista S, Cinelli E, Pantaleo T. Effects of zofenopril and ramipril on cough reflex responses in anesthetized and awake rabbits. J Cardiovasc Pharmacol Ther. 2010;15:384-92 pubmed publisher
    ..induction between 2 structurally different ACE inhibitors, namely zofenopril, which has a sulphydryl moiety, and ramipril, which has a carboxyl moiety...
  17. Mavrakanas T, Cheva A, Kallaras K, Karkavelas G, Mironidou Tzouveleki M. Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats. Pharmacology. 2010;86:85-91 pubmed publisher
    We studied the effect of the combined treatment with an angiotensin-converting enzyme (ACE) inhibitor (ramipril) and eplerenone compared with ramipril alone in streptozocin-induced diabetic rats...
  18. Zeltner R, Poliak R, Stiasny B, Schmieder R, Schulze B. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2008;23:573-9 pubmed
    ..randomized double-blind study was performed to compare the renal and cardiac effects of the ACE inhibitor ramipril and the beta-blocker metoprolol as first line therapy in ADPKD patients with hypertension...
  19. Ryu S, Kolozsvary A, Jenrow K, Brown S, Kim J. Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time. J Neurooncol. 2007;82:119-24 pubmed
    Radiation-induced optic nerve damage was reduced by ramipril, a prodrug angiotensin-converting enzyme inhibitor (ACEI)...
  20. Siriwardena A, Fairchild P, Gibson S, Sach T, Dewey M. Investigation of the effect of a countywide protected learning time scheme on prescribing rates of ramipril: interrupted time series study. Fam Pract. 2007;24:26-33 pubmed
    ..To investigate the effect of a PLT intervention for general practice to increase prescribing of ramipril for prevention of cardiovascular outcomes. Quasi-experimental, interrupted time series. Lincolnshire, UK...
  21. Wharton W, Stein J, Korcarz C, Sachs J, Olson S, Zetterberg H, et al. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis. 2012;32:147-56 pubmed
    ..conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-? (A?) levels and ACE activity, arterial ..
  22. Attia M. Spectrofluorimetric assessment of Ramipril using optical sensor Samarium ion-doxycycline complex doped in sol-gel matrix. J Pharm Biomed Anal. 2010;51:7-11 pubmed publisher
    A new, simple, sensitive and selective spectrofluorimetric method for the determination of Ramipril is developed...
  23. Thoene Reineke C, Rumschüssel K, Schmerbach K, Krikov M, Wengenmayer C, Godes M, et al. Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models. PLoS ONE. 2011;6:e23646 pubmed publisher
    The effects of AT1 receptor blocker, telmisartan, and the ACE inhibitor, ramipril, were tested head-to head and in combination on stroke prevention in hypertensive rats and on potential neuroprotection in acute cerebral ischemia in ..
  24. Wyskida K, Jura Szołtys E, Smertka M, Owczarek A, Chudek J. Factors that favor the occurrence of cough in patients treated with ramipril--a pharmacoepidemiological study. Med Sci Monit. 2012;18:PI21-8 pubmed
    Dry cough is a common cause for the discontinuation of ramipril treatment...
  25. Krikov M, Thone Reineke C, Muller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens. 2008;26:544-52 pubmed publisher
    ..with the angiotensin receptor blocker, candesartan, and the angiotensin-converting enzyme (ACE)-inhibitor, ramipril, in normotensive Wistar rats after focal cerebral ischemia, with special emphasis on the regulation of ..
  26. Gosse P, Neutel J, Schumacher H, Lacourciere Y, Williams B, Davidai G. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit. 2007;12:141-7 pubmed
    ..We compared telmisartan, an angiotensin II receptor blocker with a trough-to-peak ratio >90%, with ramipril, an angiotensin-converting enzyme inhibitor with a trough-to-peak ratio of around 50%...
  27. Galea M, Jelacin N, Bramham K, White I. Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose. Br J Anaesth. 2007;98:213-5 pubmed
    ..severe lactic acidosis, cardiorespiratory arrest, and rhabdomyolysis following an overdose of metformin and ramipril. The lactic acidosis was successfully treated with early high-volume continuous veno-venous haemofiltration...
  28. Sandmann S, Li J, Fritzenkötter C, Spormann J, Tiede K, Fischer J, et al. Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. Blood Press. 2006;15:116-28 pubmed
    ..Male Wistar rats were treated with placebo, the angiotensin-converting enzyme (ACE) inhibitor ramipril (1 mg/kg/day), or the AT1 receptor antagonist, olmesartan (1 mg/kg/day), both initiated 1 week before induction ..
  29. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487-96 pubmed publisher
    The prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure study addresses the issue of whether progression to manifest hypertension in patients with high-normal ..
  30. Cialdai C, Giuliani S, Valenti C, Tramontana M, Maggi C. Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:455-61 pubmed publisher
    ..The present study investigated the effect of zofenopril and ramipril on cough induced by citric acid in guinea pig and the involvement of bradykinin (BK) and prostaglandin E2 (PGE2) ..
  31. Zidek W, Schrader J, Lüders S, Matthaei S, Hasslacher C, Hoyer J, et al. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol. 2008;7:22 pubmed publisher
    ..Therefore the role of these agents in preventing diabetes is still not well defined. Ramipril is an ACE inhibitor (ACEi), that has been shown to reduce cardiovascular events in high risk patients and post-..
  32. Esposito R, Giammarino A, De Blasio A, Martinelli V, Cirillo F, Scopacasa F, et al. Ramipril in post-renal transplant erythrocytosis. J Nephrol. 2007;20:57-62 pubmed
    ..At study entry, blood chemistry and ACE-gene polymorphism were measured. ACEI (ramipril) was initiated at 1...
  33. Flammer A, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 2008;117:2262-9 pubmed publisher
    ..inhibitors in atherosclerotic vascular disease, it was the aim of the present study to delineate the impact of ramipril on endothelial function as well as on markers of inflammation and oxidative stress in patients with rheumatoid ..
  34. Hobbs S, Thomas M, Bradbury A. Manipulation of the renin angiotensin system in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2004;28:573-82 pubmed
    The Heart Outcomes Prevention Evaluation (HOPE) study has provided evidence for the use of ramipril for secondary cardiac prevention for patients with peripheral arterial disease...
  35. Warner G, Perry C. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs. 2002;62:1381-405 pubmed
    b>Ramipril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which is rapidly hydrolysed after absorption to the active metabolite ramiprilat...
  36. Linz W, Schaper J, Wiemer G, Albus U, Schölkens B. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992;107:970-5 pubmed
    ..banding were subjected to chronic oral treatment for one year with an antihypertensive dose of the ACE inhibitor, ramipril 1 mg kg-1 daily, (RA 1 mg) or received a low dose of 10 micrograms kg-1 daily (RA 10 micrograms) which did not ..
  37. Ko S, Kwon H, Kim S, Moon S, Ahn Y, Song K, et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun. 2004;316:114-22 pubmed
    We evaluated whether ramipril, one of long-acting ACEIs, has a direct effect on pancreas islets in animal model of type 2 diabetes. OLETF rats were treated with ramipril for 24 weeks...
  38. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/. Am Heart J. 2004;148:52-61 pubmed
    ..Primary objectives of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) are to determine if the combination of the ARB telmisartan and the ACE inhibitor ..
  39. Brown N, Kumar S, Painter C, Vaughan D. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension. 2002;40:859-65 pubmed
    ..5 mg/d, and (2) before and 1, 3, 4, and 6 weeks after addition of ramipril (escalated to 10 mg/d) or losartan (escalated to 100 mg/d). Hydrochlorothiazide decreased systolic (P=0...
  40. Gross O, Beirowski B, Koepke M, Kuck J, Reiner M, Addicks K, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 2003;63:438-46 pubmed
    ..Using the COL4A3 -/- mouse, an animal model for human AS, we evaluated therapy with ramipril in mice. One hundred and twenty-two Alport-mice were treated with 10 mg/kg/day ramipril added to drinking water...
  41. Kim J, Brown S, Kolozsvary A, Jenrow K, Ryu S, Rosenblum M, et al. Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat Res. 2004;161:137-42 pubmed
    ..The present study was carried out to determine whether ramipril, one of the inhibitors of ACE, would ameliorate radiation-induced brain damage, using a well-characterized optic ..
  42. Agodoa L, Appel L, Bakris G, Beck G, Bourgoignie J, Briggs J, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-28 pubmed
    ..Incidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown, especially among African Americans...
  43. Mann J, Gerstein H, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36 pubmed
    ..To determine whether mild renal insufficiency increases cardiovascular risk and whether ramipril decreases that risk. Post hoc analysis...
  44. Williams B, Gosse P, Lowe L, Harper R. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24:193-200 pubmed
    To compare the efficacy and safety of once-daily telmisartan and ramipril on blood pressure (BP) reductions during the last 6 h of the dosing interval...
  45. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2003;107:960-5 pubmed
    The HOPE study has demonstrated that ramipril is beneficial (ie, prevents cardiovascular death, myocardial infarction, and stroke) for a broad range of patients without evidence of left ventricular dysfunction or heart failure who are at ..
  46. Sebekova K, Gazdikova K, Syrova D, Blazicek P, Schinzel R, Heidland A, et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens. 2003;17:265-70 pubmed
    ..defence, we investigated, in patients with nondiabetic nephropathy, the short-term effect of the ACEI ramipril on parameters of oxidative stress, such as advanced glycation end products (AGEs), advanced oxidation protein ..
  47. Poirier L, de Champlain J, Larochelle P, Lamarre Cliche M, Lacourciere Y. A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. Blood Press Monit. 2004;9:231-6 pubmed
    ..the study was to compare the antihypertensive effects and the duration of action of telmisartan, amlodipine and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure (ABP) monitoring...
  48. Seeland U, Kouchi I, Zolk O, Itter G, Linz W, Bohm M. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol. 2002;34:151-63 pubmed
    ..We examined the effects of ramipril alone or with furosemide on ECM in a heart failure model...
  49. Gerstein H, Yusuf S, Holman R, Bosch J, Pogue J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 2004;47:1519-27 pubmed
    ..People with impaired fasting glucose or impaired glucose tolerance were randomised to ramipril (15 mg/day) or placebo and rosiglitazone (8 mg/day) or placebo with a 2x2 factorial design...
  50. Levitt D, Schoemaker R. Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat. BMC Clin Pharmacol. 2006;6:1 pubmed
    ..al for the pharmacokinetics of ramiprilat and its prodrug ramipril. It describes the time course of the inhibition of the N and C ACE sites in plasma and the different tissues...
  51. Sharpe N. The HOPE TIPS: the HOPE study translated into practices. Cardiovasc Drugs Ther. 2005;19:197-201 pubmed
    The HOPE TIPS study assessed the practicality and tolerability of ramipril titration to a target dose of 10 mg (as achieved in definitive efficacy studies) in a clinical practice setting...